Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

KAG 301-Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (Kos 953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple


Collapse Overview 
Collapse sponsor award id
KAG


Collapse Biography 

Collapse Time 
Collapse start date
2008-08-27

Collapse end date
2010-08-26